The health care sector closed the day down 0.2%. iBio Inc ( IBIO), Pressure BioSciences Inc ( PBIO), Amylin Pharmaceuticals Inc ( AMLN), and Neoprobe Corporation ( NEOP) were all winners today within the health care sector with Celgene Corporation ( CELG) being today's featured health care winner. Celgene Corporation rose 64 cents (1%) to $65.95 on light volume. Throughout the day, 2.5 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 4.2 million shares.

Celgene Corporation, an integrated biopharmaceutical company, discovers, develops, and commercializes various therapies to treat cancer and immune-inflammatory related diseases. Celgene Corporation has a market cap of $30.2 billion and is part of the drugs industry. The company has a P/E ratio of 30.1, below the average drugs industry P/E ratio of 30.4 and above the S&P 500 P/E ratio of 17.7. Shares are up 11.4% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Celgene as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Telik Inc ( TELK), Poniard Pharmaceuticals Inc ( PARD), AspenBio Pharma Inc ( APPY), and AspenBio Pharma Inc ( APPYD) were all losers within the health care sector with Valeant Pharmaceuticals International Inc ( VRX) being today's health care sector Loser Spotlight stock.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).